NfL has undoubtedly proven to be a valuable prognostic biomarker, but the fact that it is released, and subsequently detected, upon neuronal death, classifies NfL as a biomarker for neuronal degeneration, rather than a specific biomarker to track HD progression since prodromal phases. This evidence concerns the gene NEFL and Huntington disease.